Artivion, Inc. SEC Filings

Juniper Investment-affiliated reporting persons amended their Schedule 13D to report a decrease in their beneficial ownership of Artivion, Inc. common stock to 1,864,449 shares, representing approximately 4.0% of outstanding shares as of the record date. Between June 17, 2025 and August 11, 2025 Juniper Targeted Opportunities, L.P. sold 233,715 shares in the open market for an aggregate sale price of approximately $9,540,725, which includes brokerage commissions. Percentages are calculated using 47,183,656 shares outstanding as of August 1, 2025.

The filing breaks out ownership by entity: Juniper Fund holds 1,473,656 shares (about 3.1%), Juniper Targeted Opportunities holds 377,308 shares (about 0.8%), and Juniper Multi-Strategy holds 13,485 shares (about 0.0%). Juniper Investment Company and the named managing members may be deemed to beneficially own the aggregate shares but disclaim ownership for other purposes. The amendment references a Joint Filing Agreement and a schedule of transactions as exhibits.

Amy Horton, Vice President and Chief Accounting Officer of Artivion, reported exercising 7,992 stock options and selling the same 7,992 shares on 08/08/2025. The options had an exercise price of $29.62 and the shares were sold at $38.49, producing an approximate per-share gain of $8.87. After these transactions she directly owns 146,651 shares.

The sale was effected pursuant to a 10b5-1 trading plan adopted March 13, 2025. The exercised options vest at 33 1/3% per year beginning on the first anniversary of the grant; the first exercisable date was March 5, 2020 and the options expire March 5, 2026.

Artivion, Inc. appointed Lance A. Berry as Chief Operating Officer effective August 11, 2025, while he will continue serving as the company’s Chief Financial Officer, Treasurer and Principal Financial Officer. Mr. Berry, age 53, has been the company’s CFO and Treasurer since December 4, 2023. His compensation as COO and continued CFO includes an annual base salary of $540,000, an annual cash incentive with a bonus target of 70% of base salary, and, starting in 2026, a target equity grant valued at $2,250,000 divided equally between Performance Share Units and Restricted Stock Units.

Marshall S. Stanton, M.D., Senior Vice President, Clinical Research and Chief Medical Officer, notified the company of his decision to retire effective March 31, 2026. The retirement was stated to be not related to any disagreements with the company, and the company expects Dr. Stanton to provide strategic advice and transition services for up to one year following his retirement, with terms of that arrangement still being finalized.

Artivion filed a Form 144 reporting a proposed sale of 7,992 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $307,612.08. The filing lists total shares outstanding as 47,183,658 and shows the securities were acquired on 08/08/2025 via a stock option exercise with payment made in cash.

The filer reports “Nothing to Report” for sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information. The notice is a formal Rule 144 disclosure of a planned insider sale.

Artivion, Inc. filed a Form S-8 to register 3,570,000 additional shares of common stock for issuance under its 2020 Equity and Cash Incentive Plan. The Board increased authorized Plan shares on March 26, 2025 and stockholders approved the increase on May 13, 2025. The filing incorporates prior S-8 registrations of 2,675,000 and 3,040,000 shares and incorporates specified annual, quarterly and current reports by reference. Signatures execute the registration on August 8, 2025.

Artivion (AORT) Q2-25 10-Q highlights

• Revenue rose 15% YoY to $113.0 m; product sales +19% (notably aortic stent grafts +24%, On-X valves +24%), while preservation services +3%.
• Profitability: Gross margin expanded to $73.1 m (64.7% of sales) vs $63.3 m. Operating income improved 29% to $8.4 m, but six-month operating income fell sharply to $10.5 m (vs $31.8 m) due to higher SG&A (+17%) and a $2.7 m debt-conversion inducement.
• Net income swung to $1.3 m (EPS $0.03) from a $2.1 m loss; YTD net income slipped to $0.8 m (EPS $0.02) vs $5.4 m.
• Cash flow: Operating cash outflow of $1.9 m vs $0.6 m inflow prior year; FCF negative $8.9 m after $6.9 m capex.
• Balance sheet: Long-term debt cut to $215.5 m from $314.2 m after exchanging $99.5 m of 4.25% convertible notes for 4.33 m shares. Total liabilities down $94 m; equity up to $419.9 m. Cash steady at $53.5 m.
• Liquidity & covenants: Company remains within leverage covenant (<6.25x); Term Loan ($190 m) carries 10.6% interest, Revolver drawn $30 m.
• Strategic moves: Amended Endospan option lowers potential acquisition price to $175 m and funds additional $25 m loans (FV $10.3 m). Adopted ASU 2024-04 for debt conversions. OBBBA tax law impact under evaluation.

Overall, Q2 shows solid top-line momentum and deleveraging, offset by weak cash generation, elevated interest costs and mixed preservation-service trends.

Filing overview: FMR LLC and Abigail P. Johnson report beneficial ownership of 2,288,030.10 shares of Artivion common stock, representing 5.4% of the class. FMR LLC discloses sole voting power of 2,285,792 shares and sole dispositive power of 2,288,030.10 shares. Abigail P. Johnson reports sole dispositive power of 2,288,030.10 shares and no voting power.

The filing certifies these shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The submission references an Exhibit 99 13d-1(k)(1) agreement and a previously incorporated power of attorney for authorized signatures.

BlackRock, Inc. has filed Amendment No. 4 to Schedule 13G revealing a 5,950,909-share position in Artivion, Inc. (AORT) as of 30 June 2025. The stake equals 13.9 % of the outstanding common stock, giving BlackRock sole voting authority over 5,884,199 shares and sole dispositive authority over all 5,950,909 shares; no shared authority is reported.

The disclosure is made pursuant to Rule 13d-1(b) with BlackRock classified as a parent holding company/control person (HC). Management certifies the shares are held in the ordinary course, without intent to influence control. The filing notes that the iShares Core S&P Small-Cap ETF, a BlackRock vehicle, independently owns more than 5 % of Artivion’s float.

A double-digit passive stake from the world’s largest asset manager enhances Artivion’s institutional ownership base and may support liquidity, but the absence of activist language suggests no immediate strategic impact.